Timing and choice of androgen ablation

Prostate Cancer and Prostatic Diseases

Volumn 7, Issue 3, 2004, Pages 217-222

  Kirk, David ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

Hormone therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ESTROGEN; FLUTAMIDE; FOLLITROPIN; GONADORELIN; GONADORELIN DERIVATIVE; GOSERELIN; LEUPRORELIN; LUTEINIZING HORMONE; POLYESTRADIOL PHOSPHATE; PROGESTERONE; TESTOSTERONE; TRIPTORELIN;

ADVANCED CANCER; ANEMIA; CANCER HORMONE THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEFERRED TREATMENT; DRUG ADMINISTRATION ROUTE; DRUG FATALITY; DRUG INTERMITTENT THERAPY; FATIGUE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HOT FLUSH; HUMAN; IATROGENIC DISEASE; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MALE; MASTALGIA; MOOD DISORDER; MUSCLE ATROPHY; MUSCLE MASS; ORCHIECTOMY; OSTEOLYSIS; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT GAIN; MORTALITY; PROSTATE TUMOR; TIME;

ANDROGEN ANTAGONISTS; HUMANS; MALE; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 16644372625     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500733     Document Type: Review

References (28)

1. Rabbini F, Gleave ME. Treatment of metastatic prostate cancer: Endocrine therapy. In: Hamdy FC, Basler JW, Neal DE, Catalona WJ (eds.) Management of Urologic Malignancies, Churchill Livingstone, Edinburgh, 2002; pp. 210-226.
2. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. Br J Urol 1997; 79: 235-246.
3. Bolla M et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.
4. Nelson JB, Leper H. Prostate cancer: Radical prostatectomy. In follow-up strategies and management in urologic oncology Urol Clin N Am 2003; 30: 703-723.
5. See WA et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localised or locally advanced prostate cancer: First analysis of the early prostate cancer program. J Urol 2002; 168: 429-435.
6. Schröder FH. Endocrine treatment of prostate cancer - recent developments and the future. Part 1: Maximal androgen blockade. Early vs delayed endocrine treatment and side effects. Br J Urol Int 1999; 83, (European Urology Update Series) 161-170.
7. Holberg L et al. A randomised trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 247: 781-789.
8. Prostate Cancer Trialist's Collaborative Group. Meta-analysis of trials of immediate versus deferred hormone therapy in prostate cancer (unpublished data).
9. Soloway MS et al. Zoladex versus orchiectomy in treatment of advanced prostate cancer: A randomised trial. Urology 1991; 37: 46-51.
10. Kaisary AV et al. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostate cancer. Br J Urol 1991; 67: 502-508.
11. Botto H, Richard F, Mathieu F, Camey M. Decapeptyl in the treatment of metastatic prostatic cancer. Comparative study with pulpectomy. In: Prostate Cancer, Part A: Research, Endocrine Treatment, and Histopathology. Alan R Liss, Inc,, 1987; pp. 199-296.
12. The Leuprolide Study Group. Leuprolide vs diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984; 311: 1281-1286.
13. Mahler C. Is disease flare a problem? Cancer 1993; 72: 3799-3802.
14. Ellis WJ, Grayhack JT. Sexual function in aging males after orchiectomy and estrogen therapy. J Urol 1963; 89: 895-899.
15. Radlmier A, Bormacher K, Neumann F. Hot flushes: Mechanism and prevention. Prog Clin Biol Res 1990; 359: 131-140.
16. Morley JE, Kaiser FE, Hajjar R, Perr III HM. Testosterone and frailty. Clin Geriat Med 1997; 13: 655-695.
17. Gardiner RA et al. Cognition and hormonal manipulation in prostate cancer. Br J Urol Int 2000; 86 (Suppl 3): 218-219.
18. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439-444.
19. Hamdy NAT. The use of bisphosphonates in prostate carcinoma metastatic to the skeleton. In: Hamdy FC, Basler JW, Neal DE, Catalona WJ (eds). Management of Urologic Malignancies. Churchill Livingstone, Edinburgh,, 2002; pp. 244-248.
20. Goldenberg SL, Bruckovsky N. Use of cyproterone acetate in prostate cancer. Urol Clin N Am 1991; 18: 111-122.
21. Iversen P et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow up. J Urol 2000; 164: 1579-1582.
22. Byar DP. The Veterans Administration Cooperative Research Group's studies of cancer of the prostate. Cancer 1973; 32: 1126-1130.
23. Bishop MC. Experience with low-dose oestrogen in the treatment of advanced prostate cancer: A personal view. Br J Urol 1996; 78: 921-928.
24. Carlstrom K et al. Possible bone-preserving capacity of high dose intramuscular depot oestrogen as compared to orchiectomy in the treatment of patients with prostatic carcinoma. The Prostate 1997; 31: 193-197.
25. Hedlund PO et al. Parenteral oestrogen versus combined androgen deprivation in the treatment of metastatic prostate cancer. Scand J Urol Nephrol 2002; 36: 405-413.
26. Ockrim JL et al. Transdermal estradiol therapy for advanced prostate cancer - forward to past? J Urol 2003; 169: 1735-1737.
27. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 2000; 355: 1491-1498.
28. Goldenberg SL et al. Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology 1995; 45: 839-844.